https://www.thebodypro.com/author/polly-clayden

Latest by Polly Clayden

Equivalent Efficacy With Lower Dose Darunavir Img

Equivalent Efficacy With Lower Dose Darunavir

A reduced dose of darunavir boosted with ritonavir was effective in two reports from Italy and Spain.

Lower Dose Efavirenz Effective in Two Studies Img

Lower Dose Efavirenz Effective in Two Studies

Efavirenz dosed at 400 mg daily remained non-inferior to 600 mg at 96 weeks, and 300 mg was effective as maintenance HIV therapy, according to data from efavirenz two-dose reduction studies presented at the 2014 HIV Drug Therapy Glasgow Congress.

Savings to the NHS Predicted From Switching to Generic Antiretrovirals Img
News

Savings to the NHS Predicted From Switching to Generic Antiretrovirals

If everyone on HIV treatment in the UK switched from patented originator antiretrovirals to generics, there is the potential to save £1.25 billion in NHS drug costs over the next five years (2015-2019), according to modelling data presented at the 20...

Efavirenz-Associated Gynaecomastia Reported in South Africa Img

Efavirenz-Associated Gynaecomastia Reported in South Africa

Efavirenz-associated gynaecomastia (benign proliferation of glanular breast tissue in males) has been frequently reported to the South African national HIV and TB healthcare workers hotline. Results from a study conducted to look at this phenomenon w...

Higher ART Coverage Is Associated With Lower HIV Infection Rates in a Multi-Country Analysis Img
Conference Coverage

Higher ART Coverage Is Associated With Lower HIV Infection Rates in a Multi-Country Analysis

If all low- and middle-income countries had achieved the same level of antiretroviral treatment (ART) coverage as Botswana in 2012, 65% of new HIV infections and 70% of HIV-related deaths could have been prevented -- according to an analysis presente...

Pill A, Pill B: Simplified Second-Line Treatment for Low-Income Countries Img
Conference Coverage

Pill A, Pill B: Simplified Second-Line Treatment for Low-Income Countries

A one pill, once-daily fixed dose combination (FDC) second-line regimen might be feasible for low-income countries according to a clinical development program presented at AIDS 2014.

Introducing the 2014 Pipeline Report on HIV, Hepatitis C Virus (HCV) and Tuberculosis (TB) Img
Hepatitis C

Introducing the 2014 Pipeline Report on HIV, Hepatitis C Virus (HCV) and Tuberculosis (TB)

Last year we wrote:

[Getting] the best drugs to the most people as quickly as possible ... requires that the compounds and combination products be:

Discovered and developed in a high-quality research program; Approved by a national or multinati...

Better Late Than Never: Efavirenz Dose Optimization Img

Better Late Than Never: Efavirenz Dose Optimization

Research is emerging that Sustiva -- one of the drugs in Atripla, and a major culprit of neurological side effects among people who take it -- doesn't actually need to be taken at its commonly prescribed dose.

Promo Image
Children (Ages 0-17)

Pediatric Pipeline: CROI 2014 Update on New Antiretrovirals for Children

Several posters at CROI 2014 reported data on antiretrovirals in the paediatric pipeline. These included the new integrase inhibitor class -- which might be a useful option for children in the future.

**

Rilpivirine

Rilpivirine is an NNRTI, approv...

Bone Disease and Older HIV-Positive Women Img
Bone

Bone Disease and Older HIV-Positive Women

Still poorly understood in the medical community, bone disease in older HIV-positive women was the topic at hand in a talk from Dr. Savannah Cardew at the 4th International Workshop on Women & HIV.